Lima Elisangela da Costa, Camarinha Barbara Dias, Ferreira Bezerra Nathalia Cristina, Panisset Anderson Gonçalves, Belmino de Souza Raquel, Silva Marcus Tolentino, Lopes Luciane Cruz
Pharmacy School, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.
Instituto de Puericultura e Pediatria Martagão Gesteira, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.
Front Pharmacol. 2020 Dec 3;11:555407. doi: 10.3389/fphar.2020.555407. eCollection 2020.
Children are exposed to drug-drug interactions (DDI) risks due to their organism's complexity and the need for several medicines prescriptions in pediatric intensive care units (PICU). This study aimed to assess the prevalence of potential DDIs in a Brazilian PICU. We carried out a cross-sectional study at a pediatric teaching hospital from Rio de Janeiro (Brazil) over one year. Potential DDIs (pDDIs) between prescribed medicines for hospitalized children in PICU ( = 143) were analyzed according to severity using Micromedex. Sex, age group, number of drugs prescribed, vasoactive amines use (a proxy of clinical complexity), and the PICU length of stay were summarized using descriptive statistics. Association between the PICU length stay, and variables sex, age, clinical condition complexity, number of drugs prescribed, and severity of pDDI were examined by univariate and multiple linear regression. Seventy percent of patients aged three days to 14 years old were exposed at least one potential DDIs during PICU stay. Two hundred eighty-four different types of pDDIs were identified, occurring 1,123 times. Nervous system drugs were implicated in 55% of the interactions, and fentanyl (10%) was most involving in pDDIs. Most pDDIs were classified as higher severity (56.2%), with reasonable documentation (64.6%) and unspecified onset time (63.8%). Worse clinical condition, ten or more drugs prescribed, and most severe pDDIs were associated with a longer PICU length of stay. Multiple linear regression analysis showed an increase of 9.83 days (95% confidence interval: 3.61-16.05; = 0.002) in the PICU length of stay in children with major or contraindicated pDDIs. The results of this research may support the monitoring and prevention of pDDIs related to adverse events in children in intensive care and the design and conduction of new studies.
由于儿童机体的复杂性以及儿科重症监护病房(PICU)中需要开具多种药物处方,儿童面临药物相互作用(DDI)风险。本研究旨在评估巴西一家PICU中潜在DDI的发生率。我们在巴西里约热内卢的一家儿科教学医院进行了为期一年的横断面研究。使用Micromedex根据严重程度分析了PICU中住院儿童(n = 143)所开处方药物之间的潜在DDI(pDDI)。使用描述性统计方法总结了性别、年龄组、所开药物数量、血管活性胺的使用情况(临床复杂性的一个指标)以及PICU住院时间。通过单变量和多元线性回归分析了PICU住院时间与性别、年龄、临床病情复杂性、所开药物数量以及pDDI严重程度之间的关联。70%年龄在3天至14岁的患者在PICU住院期间至少暴露于一种潜在DDI。共识别出284种不同类型的pDDI,发生了1123次。55%的相互作用涉及神经系统药物,其中芬太尼(10%)在pDDI中最为常见。大多数pDDI被归类为更高严重程度(56.2%),有合理的记录(64.6%)且发作时间未明确说明(63.8%)。病情较差、开具十种或更多药物以及最严重的pDDI与PICU住院时间延长有关。多元线性回归分析显示,患有主要或禁忌pDDI的儿童PICU住院时间增加了9.83天(95%置信区间:3.61 - 16.05;P = 0.002)。本研究结果可能有助于监测和预防重症监护中与儿童不良事件相关的pDDI,并为新研究的设计和开展提供支持。